MVA-HBVac—A novel vaccine vector that allows pan-genotypic targeting of hepatitis B virus by therapeutic vaccination

MVA-HBVac—A novel vaccine vector that allows pan-genotypic targeting of hepatitis B virus by therapeutic vaccination

Therapeutic vaccination holds the promise to cure chronic hepatitis B virus (HBV) infection. We hypothesize that B cell, CD4, and CD8 T cell responses are necessary to overcome HBV-specific immune tolerance in chronic infection because they accompany the rare, spontaneous resolution of chronic HBV i...

Full description

Saved in:
Bibliographic Details
Main Authors: Anna D. Kosinska, Martin Kächele, Helene A. Kerth, Martin Mück-Häusl, Edanur Ates Öz, Merve Gültan, Lea Hansen-Palmus, Julia Sacherl, Chunkyu Ko, Julia Festag, Michael H. Lehmann, Carolin Mogler, Katja Steiger, Percy A. Knolle, Tanja Bauer, Asisa K. Volz, Ulrike Protzer
Format: Article
Language:English
Published: Elsevier 2025-09-01
Series:Molecular Therapy: Nucleic Acids
Subjects:
MT: Delivery Strategies
HBV
chronic hepatitis B
therapeutic vaccination
TherVacB
MVA
Online Access:http://www.sciencedirect.com/science/article/pii/S2162253125001957
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items